3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Carcinoma, Hepatocellular
28
Carcinoma, Non-Small-Cell Lung
22
Lung Neoplasms
17
Cholangiocarcinoma
13
Biliary Tract Neoplasms
13
Small Cell Lung Carcinoma
12
Triple Negative Breast Neoplasms
8
Breast Neoplasms
8
Neoplasms
6
Neoplasm Metastasis
5
Liver Neoplasms
5
Urinary Bladder Neoplasms
4
Stomach Neoplasms
4
Pancreatic Neoplasms
4
Carcinoma
4
Non-Muscle Invasive Bladder Neoplasms
3
Gallbladder Neoplasms
3
Colorectal Neoplasms
3
Adenocarcinoma Of Esophagus
3
Pathologic Complete Response
2
Ovarian Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Bile Duct Neoplasms
2
Advanced Biliary Tract Cancer
2
Adenocarcinoma of Lung
2
Adenocarcinoma
2
Vaccinia
1
SCLC, Limited Stage
1
Resectable Intrahepatic Cholangiocarcinoma
1
Interventions
pembrolizumab
3
Doxorubicin
3
Standard of Care
2
Ifosfamide
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
selinexor
1
sarilumab
1
regorafenib
1
pexidartinib
1
pertuzumab
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
durvalumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Watchful Waiting
1
Trastuzumab
1
STA 9090
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Hemangiosarcoma
×
durvalumab
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled